Multiple Myeloma

85 total trials 27 recruiting

Filter these 85 trials by phase, country, sponsor and more.

Open in Search →

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma Pending

2023-505200-33-00 5
MInimal residual Disease Adapted Strategy / IFM 2020-02 Pending

2024-513889-19-00 5
Daratumumab in Combination with Carfilzomib, Pomalidomide and Dexamethasone in patients with myeloma induced acute renal failure Pending

2024-514702-31-00 4
A multi-center open-label phase 2 study of Ixazomib, Iberdomide and dexamethasone in elderly patients with multiple myeloma at first relapse Pending

2024-516257-44-00 4
Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM): A nationwide phase 2 trial of patients with smoldering and active multiple my … Pending

2024-519353-11-00 4
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c … Recruiting

2023-507402-13-00 5 2024-04-03
Discontinuation Outcome in Multiple Myeloma after BCMA-CD3 treatment Recruiting

2025-524022-18-00 4 2026-05-22
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants with Multiple Myeloma Receiving Etentamig (ABBV- … Recruiting

2024-515770-27-00 9 2026-04-27
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratum … Recruiting

2025-520897-21-00 10 2026-02-25
A Phase 1/2 Study of Etentamig in Combination with a CELMoD Agent for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma Recruiting

2024-512146-41-00 9 2025-07-29
A phase 3, open-label, controlled, randomized study of newly diagnosed multiple myeloma treatment, designed to evaluate the efficacy and saf … Recruiting

2024-516418-39-00 5 2025-07-09
IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as p … Recruiting

2024-517325-43-00 4 2025-06-19
A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity Recruiting

2023-506260-14-00 4 2025-05-13
Phase 3 study of belantamab mafodotin, lenalidomide, and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in pa … Recruiting

2024-516030-35-00 5 2025-04-30
A Phase 1b Study of JNJ-79635322 with Daratumumab With or Without Lenalidomide or JNJ-79635322 with Pomalidomide for Multiple Myeloma Recruiting

2024-515316-44-00 3 2025-02-24
MYELOFLUDATEP: Exploratory study evaluating the value of 18F-Fludarabine PET for the initial or relapsed assessment and therapeutic evaluati … Recruiting

2024-515219-23-00 3 2024-11-08
[68Ga]Ga-PentixaFor positron emission tomography for improved risk and disease assessment in myeloma Recruiting

2022-501811-14-00 9 2024-09-20
A Window of Opportunity Trial To Learn If Linvoseltamab Is Safe And Well Tolerated, And How Well It Works In adult Participants With Recentl … Recruiting

2022-500800-24-00 4 2024-09-19
Self-administration of subcutaneous Elranatamab in the patients’ homes (ERICA) Recruiting

2023-507876-30-00 4 2024-09-04
A trial to learn if AZD0305 alone and in combination with other cancer treatments is safe and works in adults with multiple myeloma Recruiting

2023-508590-89-00 7 2024-06-25
FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – … Recruiting

2023-508586-33-00 5 2024-05-14
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezom … Recruiting

2023-507632-20-00 5 2024-05-01
A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS Recruiting

2023-505221-14-00 4 2024-04-04
A Phase 2 Study of Teclistamab in Combination with Daratumumab or Lenalidomide in Elderly Patients with Newly Diagnosed Multiple Myeloma - I … Recruiting

2024-514101-65-00 4 2023-12-21

Showing 1–24 of 85 trials